Objective: Recently, a subtype of obesity characterized as a metabolically healthy but obese (MHO) individual has been identified. However, limited data are available on these MHO individuals' metabolic and inflammatory profiles, and the effect of weight loss on these profiles. We investigated metabolic and inflammatory markers in MHO women to determine the effects of a 12-week weight loss on those markers. Subjects: One hundred and twenty-nine overweight-obese Korean women participated for 12 weeks in a clinical intervention study involving a 300 kcal/day intake reduction. The subjects were divided into two groups: MHO and metabolically abnormal obese (MAO) individuals. Methods: Computed tomography was performed. C-reactive protein (CRP), interkeukin-6 (IL-6) and oxidized low-density lipoprotein (LDL), as well as blood lipids, glucose and insulin concentrations were determined at baseline and after weight loss. Results: At baseline, plasma CRP (Po0.001), IL-6 (Po0.05) and oxidized LDL (Po0.001) levels were significantly lower in the MHO group than in the MAO group. Visceral fat at L1 (Po0.005) and visceral fat at L4 (Po0.001) were significantly lower in the MHO group than in the MAO group. The treatment induced weight loss averaging 3.11% of initial body weight, and the degree of weight loss between the two groups was similar. Visceral fat at L1 and L4 was reduced from its initial values by 3.2 and 5.4%, respectively, after weight loss. The levels of CRP (Po0.05) and oxidized LDL (Po0.01) were significantly reduced in the MAO group after the 12-week weight loss, whereas these effects were not seen in the MHO group. Conclusions: Our results showed that MHO individuals exhibited lower visceral fat accumulation and more favorable metabolic and inflammatory states than MAO individuals. After a 12-week weight loss program, significant reductions in blood lipids, CRP and oxidized LDL levels were observed in MAO individuals. However, there was no measurable effect of weight loss on lipid profiles and inflammation in MHO individuals, indicating differing effects of weight loss on these markers between MAO and MHO groups.
Introduction
Obesity is a major public health problem whose prevalence has been rising in developing countries as well as in developed countries. 1 Obesity's deleterious health effects are such that it increases the risk of many common diseases, including coronary artery disease (CAD), type 2 diabetes and hypertension. 2 Emerging evidence indicates that a metabolically healthy but obese (MHO, a subtype of obesity) individual displays insulin sensitivity, is normotensive and has favorable blood lipid profiles despite excess body fat, suggesting that obesity is a heterogeneous disorder with several possible etiologies. [3] [4] [5] [6] [7] Several reports have shown that MHO individuals comprise as much as 20-30% of the obese population, 6, 8, 9 and this uncomplicated obesity has been reported to be unrelated to cardiovascular risks. 10, 11 Brochu et al. 6 demonstrated that MHO women showed favorable blood lipid profiles and increased insulin sensitivity, which were attributed to their low amount of visceral adipose tissue and their young age at the time of their obesity's onset. More recently, Karelis et al. 12 reported that postmenopausal women with the MHO phenotype had lower levels of CRP. Despite these clinical implications, MHO individuals have not been identified as a clinical entity; thus, limited data are available on their clinical and metabolic profiles. Moreover, no studies have been conducted on the effect of weight loss on the cardiovascular risk factors in this obesity subtype population. Therefore, we investigated the blood lipid profiles, visceral fat distribution, inflammation state and LDL oxidation in MHO women and examined the effect of weight loss by calorie restriction for 12 weeks on the anthropometric and clinical parameters. The results of this study provide an understanding of the phenotypes of these MHO individuals and the recommendations for the preventative treatment of obesity.
Subjects and methods

Subjects
One hundred and twenty-nine overweight-obese women with body mass index (BMI) 425 kg/m 2 participated in a 12-week weight loss program conducted by the Clinical Nutrition Research Team at Yonsei University. All the subjects were healthy, and those subjects with type 2 diabetes, hypertension, thyroid disorders, any types of coronary heart disease or pregnancy were excluded. In addition, the subjects who were receiving any medications known to influence the variables studied were excluded. The MHO individual was defined as one who meets more than four out of five metabolic parameter criteria based on the National Cholesterol Education Program's Adult Treatment Panel III report 13 and the study of Brochu et al.: 6 homeostasis model assessment (HOMA) index o1.95, triglyceride o1.7 mmol/l, total cholesterol o5.2 mmol/l, LDL-cholesterol o2.6 mmol/l and high-density lipoprotein (HDL)-cholesterol 41.1 mmol/l. This study was approved by the Institutional Review Board of Yonsei University and all subjects gave their written informed consent to participate.
Protocol for weight loss
The subjects followed a 12-week weight loss program consisting of a 300 kcal/day reduction of their usual caloric intakes. At baseline, the subjects' usual dietary intakes were assessed using a 24-h recall method and a semiquantitative food frequency questionnaire. We used the former for analysis and the latter to ascertain whether the data collected by the 24-h recall method were representative of their usual dietary pattern. Nutrient intakes were evaluated as the mean values of a 3-day food record using CAN pro (Korean Nutrition Society, Seoul, Korea) based on the food composition table of the National Rural Living Science Institute in Korea. 14 Based on each subject's reported food intakes, an individualized and nutritionally balanced diet plan was introduced by a trained nutritionist to achieve the goal of losing a minimum of 3% of initial body weight. The instruction included food choice, cooking methods, reduction in snack consumption frequency, exchanging highcalorie foods for low-calorie, low-fat foods and limitation of simple sugar consumption. To evaluate and reinforce the subjects' compliance during the whole intervention period, the nutritionist interviewed them in a biweekly phone call and they were asked to report their 3-day food records and activities at each visit. All subjects were given verbal and written instructions on how to complete food records and activities per week throughout the study period. The subjects were instructed to record the amount of foods before ingestion, and any remaining after ingestion, by weighing the food. Total energy expenditure (TEE) (kcal/day) was calculated from activity patterns including basal metabolic rate (BMR), physical activity for 24 h 15 and specific dynamic action of the food. Each subject's BMR was calculated with the Harris-Benedict equation.
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Serum lipid profiles A blood sample was drawn after a 12-h fasting period to determine serum lipid profiles (total cholesterol, triglyceride, LDL-cholesterol and HDL-cholesterol) at baseline and at 12 weeks. Serum cholesterol and HDL-cholesterol were measured with commercially available kits (Choongwae, Seoul, Korea) by enzymatic methods. Serum triglyceride was analyzed using a total glycerol test kit (Roche, Basel, Switzerland). Low-density lipoprotein-cholesterol was estimated indirectly using the Friedewald formula; that is, LDLcholesterol ¼ total cholesterolÀ(HDLÀcholesterol þ (triglyceride/5)) for subjects with serum triglyceride levels o400 mg/dl, and measured directly for subjects with serum triglyceride levels X400 mg/dl. All measurements were carried out on a Hitachi 747 autoanalyzer (Hitachi Ltd,Tokyo, Japan).
Serum glucose, insulin and HOMA Glucose was measured by a glucose oxidase method using a Beckman Glucose Analyzer (Beckman Instruments, Irvine, CA, USA). Insulin was measured by radioimmunoassays with commercial kits from Immuno Nucleo Corporation (Stillwater, MN, USA). We measured insulin resistance using the homeostasis model, in which homeostasis model assessment-insulin resistance (HOMA-IR) ¼ fasting insulin (mU/ ml) Â glucose (mmol/l)/22.5.
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Abdominal fat distribution at levels of L1 and L4 using computed tomography scanner Abdominal fat areas were measured by computed tomography (CT) scanning using a General Electric (GE) High Speed Advantage 9800 scanner (Milwaukee, WI, USA). Two crossInflammation and weight loss in MHO individuals M-J Shin et al sectional images were made of each subject: in the abdomen at the levels of the first lumbar (L1) vertebra and fourth lumbar (L4) vertebra. Each CT slice was analyzed for its crosssectional fat area using a density control program available in the standard GE computer software. Parameters for total abdominal fat density at the L1 and L4 levels were selected in the range of À150 to À50 Hounsfield Units (HU). The total abdominal fat area was divided into visceral and subcutaneous fat areas to calculate the specific fat areas of each.
Plasma CRP, IL-6 and oxidized LDL assay Plasma CRP was measured by an Express Plus autoanalyzer (Chiron Diagnostics Co., MA, USA) using a commercially available high-sensitivity kit, CRP-Latex (II) X2 (Seiken Laboratories Ltd, Tokyo, Japan). Plasma oxidized LDL and IL-6 were measured using an enzyme-linked immunoabsorbent assay (Mercodia,Uppsala, Sweden).
Statistical analysis
The SPSS 12.0 software package (Statistical Package for Social Science, SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data are presented as mean7s.d. The distribution of postmenopausal women between the two groups was examined using the w 2 test. In the within-group test, we conducted paired t-test for biochemical parameters before and after the 12-week weight loss. In the between-group test, differences in clinical parameters between the two groups (MHO vs MAO group) were analyzed using Student's t-test. Differences were considered significant at Po0.05.
Results
The baseline characteristics of all subjects (n ¼ 129) are shown in Table 1 . Twenty-three subjects (18% of the total) were identified as MHO individuals who met the criteria of clinical markers. The remaining 106 subjects were classified as MAO individuals. Body mass index , TEE and age did not differ between the two groups. The prevalence of postmenopausal women was lower but not significantly lower among the MHO individuals (P40.05). The subjects' overall compliance with the diet plan for weight loss was good. At baseline, the estimated total caloric intakes of all subjects averaged 2402 kcal (% CHO:% PRO:% FAT ¼ 60:17:23) and were reported at 12 weeks of intervention to average 1980 kcal (% CHO:% PRO:% FAT ¼ 61:17:22). Table 2 describes anthropometric parameters before and after weight loss in both the MHO and MAO groups. The results of the CT scan showed that visceral fat at L1 (Po0.005) and visceral fat at L4 (Po0.001) were significantly lower in the MHO group than in the MAO group. The MHO group had significantly lower levels of total cholesterol (Po0.001), triglyceride (Po0.001) and LDL-cholesterol (Po0.001), but significantly higher HDL-cholesterol levels (Po0.001) ( Table 3 ). The levels of apolipoprotein (apo) AI (Po0.05) were significantly higher, and the levels of apo B (Po0.001) and HOMA-IR (Po0.005) were significantly lower, in the 
Blood lipids, CRP and LDL oxidation in MHO women
Anthropometric and clinical parameters after 12-week weight loss
Mean percentage weight changes during the 12 weeks were similar for both groups. The changes in anthropometric parameters and serum lipids after weight loss in both the MHO and MAO groups are presented in Tables 2 and 3 , respectively. Significant reductions in abdominal fat area (Table 2) , blood lipids and apo B concentrations (Table 3) were observed in the MAO group. The MHO group's blood lipid profiles, including apolipoproteins, were not significantly changed by the 12-week weight loss, whereas their subcutaneous fat area at L1 (Po0.005) and visceral fat area at L4 (Po0.005) were significantly reduced after weight loss. As shown in Figure 1 , the levels of CRP (Po0.05) and oxidized LDL (Po0.01) were significantly reduced in the MAO group, but these reductions were not seen in the MHO group. The levels of IL-6 showed no significant changes after weight loss in either group (1.5971.19 to 1.7571.12 pg/ml for MHO; 2.3671.65 to 2.1571.12 pg/ml for MAO).
Discussion
In the present study, the criteria based on the National Cholesterol Education Program guideline and HOMA-IR were employed for the classification of MHO individuals, which was suggested by Karelis et al. 18 Our results showed that 18% of the subjects had the metabolic characteristics of relatively high insulin sensitivity, low amounts of visceral fat and favorable blood lipid profiles, which confirmed the previous reports. 8, 9 Recent studies have tried to demonstrate clustering factors for the protective profiles of these MHO individuals. Brochu et al. 6 reported that lower visceral fat accumulation, even in the presence of a large amount of total body fat, is characteristic of MHO individuals and that this contributed to the protective effect they exhibit against metabolic abnormalities. The reproducible phenotypic characteristic of MHO individuals in our study was a significantly lower level of visceral fat accumulation revealed by the CT scan, which could be associated with higher insulin sensitivity in these MHO individuals.
More recently, Karelis et al. 12 reported that postmenopausal women with the MHO phenotype had lower levels of CRP. They concluded that the lower inflammation state could play a role in the protective profile of the MHO individuals. In the present study, lower levels of CRP, IL-6 and oxidized LDL were observed in MHO individuals than in MAO individuals. Given that the synthesis of CRP by the liver is largely regulated by the cytokine IL-6, 19-20 the lower CRP levels in our MHO individuals were partly attributed to their lower levels of IL-6, which is preferentially produced in Inflammation and weight loss in MHO individuals M-J Shin et al visceral adipocytes. Also, it is plausible that MAO individuals' insulin resistance increased their hepatic CRP production by attenuating insulin's effect on inhibiting acute-phase protein synthesis. 21 Our results are supported by the findings of McLaughlin et al., 22 who reported that CRP concentrations are elevated predominantly in obese individuals who are also insulin resistant. The incidence of postmenopausal in our study was higher, though not significantly higher, in MAO individuals than in MHO individuals. The metabolic and inflammatory features of both groups, however, were not changed after excluding postmenopausal subjects from the data analysis (data not shown). These results were consistent with the findings of Karelis et al., 12 which were demonstrated in postmenopausal women. The present study investigated the effect of weight loss on blood lipids, body fat, oxidized LDL and inflammatory markers. Evidence from intervention studies has demonstrated that weight loss by caloric restriction reduces several markers of inflammation, including CRP, IL-6 and tumor necrosis factor-a (TNF-a); so weight control is a widely accepted and recommended clinical goal for reducing cardiovascular risk, including systemic inflammation. 23, 24 Our results showed significant reductions in blood lipid profiles, but the levels of CRP and oxidized LDL fell only in MAO individuals despite the similar weight loss in both MHO and MAO individuals, indicating the differential effects of weight loss on clinical markers in both groups. With regard to the effect of weight loss on IL-6, we could not find a significant overall decrease in IL-6 after the 12-week weight loss period, but did find a slight tendency toward IL-6 reduction in the MAO individuals. The published reports regarding weight loss' effects on IL-6 have yielded conflicting data in terms of the degree of weight change and duration of weight loss. 25, 26 Given that the subjects remained obese after the present study's 12-week weight loss period, it seems likely that a critical amount of total adiposity must be lost before the weight loss effect on this cytokine is observed, so the adipocyte resumes a more balanced function. 27 At this time, the mechanisms regarding the different effects of weight loss shown in MHO and MAO individuals have not been elucidated. Although the MHO individuals' clinical markers did not reflect the beneficial effects of weight loss in the present study, these results should not persuade us to underestimate the positive effects of lifestyle modifications, including weight loss, on MHO individuals. According to a recently published review by Nicklas et al., 28 weight loss has a direct effect on adipose tissue, which not only decreases the production of proinflammatory mediators such as IL-6 and TNF-a, but also increases the production of anti-inflammatory mediators such as IL-10 and IL-1 receptor antagonist. In the present study, we cannot exclude the possibility that MHO individuals might experience weight loss-induced improvement in their anti-inflammatory profiles during intervention, although the improvement in proinflammatory profiles was not evident in this study. On the other hand, there is evidence that endothelial dysfunction and early atherosclerotic changes were demonstrated even in MHO individuals compared to their healthy and lean counterparts. 29 Therefore, further studies are needed to determine the clinical phenotypes, such as adipocytokine levels or anti-inflammatory profiles, and to monitor the long-term clinical implications for MHO individuals, especially in CAD. As recently evidenced by Weisberg et al., 30 adipose tissue macrophage numbers increase during obesity and participate in inflammatory pathways, and it is also of interest to characterize the changes in adipose tissue macrophage or adipocyte size with weight loss to understand the different weight loss responses in MHO individuals.
In conclusion, we demonstrated lower levels of CRP, IL-6 and oxidized LDL in MHO individuals. Moreover, the prominent weight loss effects on MAO individuals' inflammatory markers were not seen in MHO individuals. Our results provide considerable evidence of the differential effects of weight loss on inflammatory markers between MAO and MHO individuals, helping us to understand the phenotypes of uncomplicated obesity.
